Docket No.: 15652-00020-US

AMENDMENTS TO THE CLAIMS

This Listing of Claims will replace all prior versions and listings of claims in this application.

Listing of Claims:

(Previously Presented) A delayed release oral pharmaceutical dosage form comprising a core material coated with a semipermeable membrane, wherein:

> the core material is not coated with a separating layer and comprises an active ingredient selected from the group consisting of omeprazole, an alkaline salt of omeprazole, S-omeprazole and an alkaline salt of S-omeprazole, one or more alkalizing additives, one or more swelling agents, an optional starter seed and optional pharmaceutically acceptable excipients;

the semipermeable membrane is able to disrupt and comprises a single polymer composition containing a modifying agent and a water insoluble polymer selected from the group consisting of cellulose ethers, cellulose esters, polyvinyl esters and acrylic polymers; and

the dosage form does not comprise an enteric coating.

2. (Cancelled).

- 3. (Previously Presented) The dosage form according to claim 1, wherein the active ingredient is omeprazole.
- 4 (Previously Presented) The dosage form according to claim 1, wherein the active ingredient is a magnesium salt of omeprazole having a crystallinity of more than 70% as determined by X-ray powder diffraction.

5 (Previously Presented) The dosage form according to claim 1, wherein the active ingredient is a magnesium salt of S-omeprazole.

- 6. (Cancelled).
- (Previously Presented) The dosage form according to claim 1, wherein the dosage form 7. comprises individual pellets of the core material coated with the semipermeable membrane.
- 8 (Previously Presented) The dosage form according to claim 1, wherein the core material further comprises an osmotic agent.
- 9. (Previously Presented) The dosage form according to claim 1, wherein the alkalizing additive gives a pH of not less than 8.5 when measured in a 2% w/w water solution/dispersion with a pH-measuring electrode.
- 10. (Previously Presented) The dosage form according to claim 9, wherein the alkalizing additive is selected from the group consisting of disodium hydrogen phosphate, trisodium phosphate, arginine and talc.
- 11 (Cancelled).
- 12 (Previously Presented) The dosage form according to claim 1, wherein the alkalizing additive is present in an amount of 15 to 35 % by weight of the core material excluding the weight of the optional starter seed.
- 13. (Previously Presented) The dosage form according to claim 1, wherein the swelling agent is selected from the group consisting of crosslinked polyvinyl pyrrolidone, crosslinked sodium carboxymethylcellulose, sodium starch glycolate and low-substituted hydroxypropyl cellulose (L-HPC).

- 14. (Previously Presented) The dosage form according to claim 1, wherein the swelling agent is present in an amount of approximately 20 to 60% by weight of the core material excluding the weight of the optional starter seed.
- 15. (Previously Presented) The dosage form according to claim 1, wherein the swelling agent is present in an amount of 30 to 50% by weight of the core material excluding the weight of the optional starter seed.
- (Currently Amended) The dosage form according to claim 1, wherein the modifying agent is talk talc or fumed silica.
- 17. (Previously Presented) The dosage form according to claim 1, wherein the water insoluble polymer is selected from the group consisting of ethylcellulose, cellulose acetate, polyvinyl acetate, and ammonium methacrylate copolymer type A and type B.
- (Previously Presented) The dosage form according to claim 1, wherein the water insoluble polymer is present in an amount of approximately 3-30% by weight of the core material
- 19. (Cancelled).
- 20. (Previously Presented) A process for the manufacture of a delayed release dosage form as defined in claim 1, comprising forming the core material, and coating the core material with the semipermeable membrane to obtain the delayed release dosage form of claim 1.
- (Cancelled).
- 22. (Cancelled).
- 23. (Currently Amended) A method for improving inhibition of gastric acid secretion which comprises administering to a patient in need thereof, a delayed release oral pharmaceutical

dosage form according to any one of claims 1, 3-10,12-18, 28 or 29 1, 3-5, 7-10, 12-18, 28 and 29.

- 24. (Currently Amended) A method for improving the therapeutic effect in the treatment of gastrointestinal disorders associated with excess acid secretion which comprises administering to a patient in need thereof, a delayed release oral pharmaceutical dosage form according to any one of claims 1, 3-10,12-18, 28 or 29 1, 3-5, 7-10, 12-18, 28 and 29.
- 25. (Currently Amended) A delayed release oral dosage form according to any one of claims 1, 3-10,12-18, 28 or 29 1, 3-5, 7-10, 12-18, 28 and 29 filled in a capsule.
- 26. (Currently Amended) A delayed release oral dosage form according to any one of claims 1, 3-10,12-18, 28 or 29 1, 3-5, 7-10, 12-18, 28 and 29 compressed into a multiple unit tableted dosage form, optionally comprising tablet excipients.
- (Previously Presented) The dosage form according to claim 12 or 13, wherein the core material further comprises an osmotic agent.
- 28. (Previously Presented) The dosage form according to claim 1, wherein the modifying agent and water insoluble polymer are present in a weight ratio of from 80:20 to 60:40.
- (Previously Presented) The dosage form according to claim 1, wherein the starter seed is a sugar sphere.
- 30. (Previously Presented) The dosage form according to claim 1, wherein the alkalizing additive is present in an amount of approximately 5 to 35% by weight of the core material excluding the weight of the optional starter seed.
- (Previously Presented) The dosage form according to claim 1, wherein the modifying agent and water insoluble polymer are present in a weight ratio of from 90:10 to 50:50.